(NASDAQ: FULC) Fulcrum Therapeutics's forecast annual revenue growth rate of -7.04% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.39%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.86%.
Fulcrum Therapeutics's revenue in 2024 is $81,630,000.On average, 4 Wall Street analysts forecast FULC's revenue for 2024 to be $4,992,061,600, with the lowest FULC revenue forecast at $4,992,061,600, and the highest FULC revenue forecast at $4,992,061,600. On average, 1 Wall Street analysts forecast FULC's revenue for 2025 to be $2,051,799,718, with the lowest FULC revenue forecast at $2,051,799,718, and the highest FULC revenue forecast at $2,051,799,718.
In 2026, FULC is forecast to generate $5,264,128,957 in revenue, with the lowest revenue forecast at $5,264,128,957 and the highest revenue forecast at $5,264,128,957.